Mode of Histological Diagnosis in Patients With Non-small Cell Lung Cancer Treated With Chemoradiotherapy: Its Prognostic Implication, Especially in Light of the European Durvalumab Licence?

Madam – Chemoradiotherapy is the standard of care in locally advanced non-small cell lung cancer. The PACIFIC trial showed that durvalumab after chemoradiotherapy was associated with a significant survival benefit [1]. However, the European Medicines Agency restricted durvalumab approval to patients wit h PDL1-positive tumours [2]. Experts criticised this restriction as it was based on an unplanned post-hoc analysis [3].

Source: Clinical Oncology - July 1, 2019 Category: Radiology Authors: M.S. Iqbal, E. Smith, M. Cunnell, A. Greystoke Tags: Letter Source Type: research